Nadeem Mirza Email

SVP, Clinical Development . Salarius Pharmaceuticals

Houston, TX

Location

LinkedIn

Current Roles

Employees:
12
Revenue:
$2.8M
About
Salarius Pharmaceuticals (NASDAQ: SLRX) is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most. The company's lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug designation and Rare Pediatric Disease Designation by the U.S. Food and Drug Administration. Salarius believes that Seclidemstat is one of only two reversible inhibitors of the epigenetic modulator LSD1 currently in human trials, and that it could have potential for improved safety and efficacy compared to other LSD1-targeted therapies. Salarius is also developing Seclidemstat for a number of cancers with high unmet medical need, with an ongoing clinical study in Ewing sarcoma and a clinical study in advanced solid tumors, including prostate, breast and ovarian cancers. Salarius receives financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and is also the recipient of an $18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT)
Salarius Pharmaceuticals Address
2450 Holcombe Blvd
Houston, TX
United States
Salarius Pharmaceuticals Email
Salarius Pharmaceuticals Phone Numbers
346-772-0346

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.